title: Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report.
abstract: In September this year the Nuffield Council on Bioethics held a meeting to disclose and discuss the main findings of their newly published report on the ethical issues associated with developments in pharmacogenetics research. The basics of pharmacogenetics science is briefly outlined, and then the extent to which the report was successful in addressing (or at least highlighting) the attendant social, ethical, and policy implications of pharmacogenetics research is evaluated.
authors.affiliation: Centre for Family Research and Cambridge Genetics Knowledge Park, Faculty of Social and Political Sciences, University of Cambridge, Free School Lane, Cambridge, B2 3RF, UK. opc22@cam.ac.uk
authors.forename: O P
authors.initials: OP
authors.lastname: Corrigan
mesh_terms: D003219:Confidentiality; D003362:Cost-Benefit Analysis; D032984:Ethics, Research; D006801:Humans; D007258:Informed Consent; D010597:Pharmacogenetics / Q000191:economics / Q000941:ethics*; D011057:Politics; D018907:Privacy; D012107:Research Design
references.citation: Value Health. 2002 Jan-Feb;5(1):5-13
references.pmid: 11873384
references.citation: Kennedy Inst Ethics J. 2002 Mar;12(1):1-15
references.pmid: 12211263
references.citation: Lancet. 2000 Apr 15;355(9212):1358-61
references.pmid: 10776762
references.citation: BMJ. 1998 Apr 25;316(7140):1295-8
references.pmid: 9554902
references.citation: Control Clin Trials. 2002 Jun;23(3):222-39
references.pmid: 12057876
references.citation: Gut. 2003 Jan;52(1):10-1
references.pmid: 12477749
references.citation: Community Genet. 2001;4(4):204-14
references.pmid: 12751484
references.citation: Thromb Haemost. 2004 Jan;91(1):87-94
references.pmid: 14691573
references.citation: Am J Pharmacogenomics. 2002;2(4):273-81
references.pmid: 12421098
references.citation: Am J Psychiatry. 1993 Apr;150(4):678-9
references.pmid: 8507274
references.citation: Nature. 2000 Jun 15;405(6788):857-65
references.pmid: 10866212
references.citation: Nat Rev Drug Discov. 2002 Jul;1(7):541-9
references.pmid: 12120260
references.citation: BMJ. 2004 Jul 3;329(7456):15-9
references.pmid: 15231615
references.citation: Drug Discov Today. 2001 Mar 1;6(6):282-284
references.pmid: 11257574
references.citation: Trends Pharmacol Sci. 2000 Jul;21(7):247-9
references.pmid: 10871892
references.citation: JAMA. 1998 Apr 15;279(15):1200-5
references.pmid: 9555760
references.citation: Adverse Drug React Toxicol Rev. 1995 Autumn;14(3):175-91
references.pmid: 7492703
references.citation: Am J Pharmacogenomics. 2003;3(6):375-83
references.pmid: 14672518
references.citation: Am J Pharmacogenomics. 2002;2(3):207-12
references.pmid: 12383027
references.citation: Am J Pharmacogenomics. 2001;1(4):271-81
references.pmid: 12083959
references.citation: N Engl J Med. 1980 Apr 17;302(16):896-900
references.pmid: 7360175
references.citation: Soc Stud Sci. 2003 Jun;33(3):327-64
references.pmid: 14621671
references.citation: Soc Sci Med. 1997 Nov;45(9):1337-55
references.pmid: 9351153